company mission
Tisento Therapeutics did not change its basic mission between January 22, 2024 and January 9, 2026. In both versions, the company says drug development should start by listening to people affected by serious disease, then turning that understanding into treatment decisions. The core idea is stable: patient need comes first, and innovation should follow from that rather than from technology for its own sake. What changed is the level of detail and the scope of who gets counted as an input. The 2024 statement is spare and focused on patients and healthcare providers, with an emphasis on understanding daily challenges. By 2026, the language is broader and more operational: families, clinicians, regulators, and scientific data all shape the company, and the claim extends into research design, trial design, and the evolution of the company itself. The 2026 version also sharpens the mission around specific diseases. It names MELAS and other genetic mitochondrial diseases, which gives the patient-centered language an actual target. That is more concrete than the 2024 wording, which spoke in general terms about debilitating diseases without tying the mission to a named program or disease area. Evidence is thin on whether this reflects a real strategic shift or simply more polished messaging. We have two website snapshots, not internal planning documents or repeated public statements across the same period. My read: this looks less like a mission rewrite and more like a refinement, from a broad listening-first posture to a more explicit, disease-focused and trial-aware version of the same belief.